美国 Singulex   
一种信息生物分析系统能够检测血液中的心脏肌钙蛋白I(cTnI)。cTnI是已知的心肌损害的生物医学标志物。

这种新型检测方法叫做Erenna，业已证实其诊断能力符合新近重新定义的急性心肌梗塞(AMI)诊断标准，已经得到了欧洲心脏学会和美国心脏学会的重视和推荐。

这种Erenna检测方法是由Singulex公司(Haywood, CA, USA)研制开发的，使用了获得专利的直接单分子检测技术以及用户自定义的临床检测方法，能够在亚皮克(pg)水平定量检测具有治疗意义的生物标志物。研究显示Erenna能够显著降低样本背景，能够鉴别检测来自其他分子的染料，检测结果具有良好的可重复性和较好的信/噪比。

Singulex enables critical research about disease and therapeutic intervention by providing cutting edge immunodiagnostic products and personalized services.

Singulex, Inc. has pioneered single-molecule counting technology that can quantitatively measure single molecules such as proteins and metabolites directly in complex biological samples without abundant protein stripping techniques. We provide instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy.

In addition, we focus on advancing industry-leading sample analysis and custom assay development services. Our team of scientists are experts in the field of immunoassay development and our manufacturing department ensures that products are produced with the highest standards.

Leveraging upon the Singulex technology, our CVMedHome Offering empowers physicians and patients to better manage heart health with a unique cardiovascular wellness management program. The CVMedHome offering includes enhanced cardiovascular profiling services featuring ultrasensitive Sgx HD™ immunoassays, a personalized wellness program, and online interactive management tools.